AIBN is solving serious problems in health, energy and the bioeconomy
using advanced biomanufacturing, precision nanomedicine and nanoengineered materials.
Our research teams are working with industry and governments to make critical strides forward and impacts in areas that include: mRNA manufacturing and vaccine development, diagnostics to discover and treat diseases, future foods and biosustainability projects reprograming cells to help the world’s biggest companies transition to net zero.
The AIBN at a glance
Part of Australia's
#1 University500+ world-class researchers
9 co-located NCRIS Facilities
Over $250m in research revenue
100+ industry partnerships
22% of UQ’s patent portfolio is generated by the AIBN
Our impact
- An AU$3.2 million prize has been awarded to AIBN researchers and industry partner Vaxxas, to develop and distribute an easy to use, next-generation COVID-19 mRNA vaccine on the company’s needle-free patch.
- AIBN researchers are using organoids to transform our approach to addressing the world’s most serious health problems.
- The AIBN has the knowledge and infrastructure to ensure Australia can develop and deliver clinical-grade vaccines whenever, and wherever, they are needed.
Latest News
Partner with us
Contact us and learn how our scientific expertise and cutting edge facilities could help you reach your goals.
